Activity-based chemical proteomics uncovers unexpected covalent targets of E64d and reveals a role for cysteine cathepsins in PLD3 proteostasis
TL;DR
In neurons, treatment with E64d lead to about 50-fold PLD3 accumulation and dysregulation of its proteolytic cleavage, while there was only a minor overall change on the whole proteome level, which suggests that their activation might be responsible for decreased PLD3 levels in neurons of patients with Alzheimer’s diseases.
Abstract
Catalytic activity of 5′-3′ exonuclease Phospholipase D3 (PLD3) is associated with immune signaling and neurodegeneration including Alzheimer’s disease. PLD3 undergoes multiple post-translational modifications and proteolytic cleavage to establish its catalytically active form. However, the proteases catalyzing the cleavage of PLD3 have remained unidentified. To study the proteolytic cleavage of PLD3, we have evaluated the small molecule covalent inhibitor E64d that blocks proteolysis catalyzed by cysteine cathepsins. To validate the selectivity of E64d, we have designed and synthetized an E64d propargyl analogue and carried out a detailed activity-based protein profiling to reveal a broad engagement of the compound with other protein targets including bleomycin hydrolase (BLMH), Kelch-like ECH-associated protein 1 (KEAP1), transcription elongation factor SPT5 (SUPT5H) and asparagine synthetase (ASNS). The specificity of the E64d-protein interactions was confirmed by biochemical assays and mass spectrometry-based site identifications. In neurons, treatment with E64d lead to about 50-fold PLD3 accumulation and dysregulation of its proteolytic cleavage, while there was only a minor overall change on the whole proteome level. Taken together, this study provides insights into previously unknown E64d selectivity and renders cysteine cathepsins responsible for PLD3 degradation in neurons. It highlights the importance of cysteine cathepsins activity in neuronal lysosomes for proper PLD3 processing and hence it suggests that their activation might be responsible for decreased PLD3 levels in neurons of patients with Alzheimer’s diseases. These findings are key for further elucidation of PLD3 function in neurodegenerative diseases.